Browsing Tag

Caribou

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1…

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell…
Read More...

<!--…
Read More...

-- CaMMouflage Phase 1 clinical trial to initiate patient enrollment at dose level 1 in early 2023 -- -- CB-011 is…
Read More...

BERKELEY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading…
Read More...

BERKELEY, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading…
Read More...

BANGOR, MAINE, May 07, 2022 (GLOBE NEWSWIRE) -- After two years of online and outdoor Commencement exercises due to…
Read More...

BERKELEY, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading…
Read More...

BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading…
Read More...

BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading…
Read More...

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key…
Read More...